title: Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
abstract: Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.
authors.affiliation: Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France. pierre.fenaux@avc.aphp.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.forename: David
authors.initials: D
authors.lastname: Bowen
authors.forename: Norbert
authors.initials: N
authors.lastname: Gattermann
authors.forename: Eva
authors.initials: E
authors.lastname: Hellström-Lindberg
authors.forename: Wolf-Karsten
authors.initials: WK
authors.lastname: Hofmann
authors.forename: Michael
authors.initials: M
authors.lastname: Pfeilstöcker
authors.forename: Guillermo
authors.initials: G
authors.lastname: Sanz
authors.forename: Valeria
authors.initials: V
authors.lastname: Santini
mesh_terms: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D012306:Risk
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine